CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Compass Pathways PLC (CMPS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent Phase 3 trial success, strong analyst upgrades, and significant funding raise position it well for future growth. While the stock has experienced slight price declines recently, the long-term potential in the treatment-resistant depression market, coupled with positive sentiment from hedge funds and analysts, makes it a strong candidate for investment.
The MACD is above 0 and positively contracting, indicating a bullish trend. The RSI is neutral at 47.379, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are S1: 6.183 and R1: 8.574, with the pivot at 7.379. The stock is trading slightly below the pivot, which may present a good entry point for long-term investors.
Successful Phase 3 trial results for COMP360, meeting primary endpoints with statistical significance.
Analysts have raised price targets significantly, with targets ranging from $15 to $22 and maintaining Buy/Outperform ratings.
The company raised $200 million through warrant exercises, ensuring financial stability for future clinical trials.
Hedge funds have increased their buying activity by 302.54% over the last quarter.
The mental health therapeutics market is projected to exceed $40 billion, providing a favorable macroeconomic backdrop.
Slight price decline in the regular market (-1.48%) and pre-market (-2.42%), which may indicate short-term weakness.
High historical volatility (106.
and implied volatility (83.39), which could lead to price fluctuations.
Competition from Helus Pharma's SPL026, which also showed strong results in treatment-resistant depression trials.
In Q3 2025, Compass Pathways reported a net income of -$137.7 million, a significant improvement of 257.69% YoY. EPS also improved to -1.44, up 157.14% YoY. However, revenue remains at 0, reflecting the company's pre-revenue stage as it focuses on clinical development.
Analysts are highly optimistic about CMPS, with multiple firms raising price targets recently. Canaccord increased its target to $20, Morgan Stanley to $18, and RBC Capital to $22, all maintaining Buy or Outperform ratings. Analysts highlight the potential for COMP360 to become the first FDA-approved classical psychedelic therapy for treatment-resistant depression, with durable effects and a clean safety profile.
